Relationship between Treatment Plan Dosimetry, Toxicity, and Survival following Intensity-Modulated Radiotherapy, with or without Chemotherapy, for Stage III Inoperable Non-Small Cell Lung Cancer.
NSCLC
dosimetric parameters
overall survival
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Nov 2021
25 Nov 2021
Historique:
received:
24
09
2021
revised:
20
11
2021
accepted:
22
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Concurrent chemoradiotherapy (cCRT) is the preferred treatment for stage III NSCLC because surgery containing multimodality treatment is often not appropriate. Alternatives, often for less fit patients, include sequential CRT and RT alone. Many reports describing the relationship between overall survival (OS), toxicity, and dosimetry are based on clinical trials, with strict criteria for patient selection. We performed an institutional analysis to study the relationship between dosimetric parameters, toxicity, and OS in inoperable patients with stage III NSCLC treated with (hybrid) IMRT/VMAT-based techniques in routine clinical practice. Eligible patients had undergone treatment with radical intent using cCRT, sCRT, or RT alone, planned to a total dose ≥ 50 Gy delivered in ≥15 fractions. All analyses were performed for two patient groups, (1) cCRT (
Identifiants
pubmed: 34885034
pii: cancers13235923
doi: 10.3390/cancers13235923
pmc: PMC8657053
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):688-696
pubmed: 31514942
Lung Cancer. 2021 May;155:103-113
pubmed: 33774382
Sci Rep. 2021 Mar 15;11(1):5939
pubmed: 33723301
Oncologist. 2021 Feb;26(2):e306-e315
pubmed: 33145902
J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987
pubmed: 31196455
J Thorac Oncol. 2016 Apr;11(4):566-72
pubmed: 26773741
Cancer Treat Rev. 2010 Aug;36(5):393-9
pubmed: 20181430
Lung Cancer. 2017 Jun;108:222-227
pubmed: 28625640
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):775-81
pubmed: 19515503
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
Ann Oncol. 2013 Oct;24 Suppl 6:vi89-98
pubmed: 23860613
J Thorac Oncol. 2017 Feb;12(2):293-301
pubmed: 27743888
J Clin Oncol. 2016 Mar 20;34(9):953-62
pubmed: 26811519
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):690-6
pubmed: 24035329
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50
pubmed: 22682812
Lung Cancer. 2020 Nov;149:68-77
pubmed: 32979634
Ann Oncol. 2020 Feb;31(2):191-201
pubmed: 31959336
Radiother Oncol. 2020 Feb;143:66-72
pubmed: 31431389
Clin Lung Cancer. 2011 Jul;12(4):252-7
pubmed: 21726825
Acta Oncol. 2014 Mar;53(3):316-23
pubmed: 23957648
Lung Cancer. 2021 Feb;152:149-156
pubmed: 33418430
Acta Oncol. 2015 Mar;54(3):427-32
pubmed: 25383450
Radiat Oncol. 2018 Oct 5;13(1):196
pubmed: 30290823
Acta Oncol. 2015;54(9):1343-9
pubmed: 26198657
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):927-934
pubmed: 29976505
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):357-66
pubmed: 19660879
Clin Lung Cancer. 2016 Sep;17(5):398-405
pubmed: 26936682
Cochrane Database Syst Rev. 2010 Jun 16;(6):CD002140
pubmed: 20556756
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):514-524
pubmed: 31306734
Lung Cancer. 2017 Aug;110:14-18
pubmed: 28676212
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e297-303
pubmed: 22579380
Radiother Oncol. 2018 Apr;127(1):1-5
pubmed: 29605476
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1087-96
pubmed: 16682145
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064